While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report released in Clinical Infectious Diseases shows.
The report, an update of progress toward the Infectious Diseases Society of America (IDSA)'s 10 x '20 initiative to see FDA approval of 10 new systemic antibacterial agents by 2020, follows a 2013 report on the status of the antibacterial drug pipeline.
While the numbers of antibiotics annually approved for marketing in the U.S. has increased following a decline in the previous decade, the authors found, the most recently approved drugs represent modifications to existing classes, rather than innovative approaches. With some momentum propelled by antibiotic incentives enacted in the last few years as well as by increased funding for NIAID and BARDA, the report finds that unmet needs persist, with far too few treatment options available for multidrug resistant infections. At the same time, while larger pharmaceutical companies continue to leave the field, the small companies that are responsible for most of the antibiotic innovation are struggling to stay in business, the authors note.antibiotics
Highlighting needs for additional incentives to stabilize the antibiotic market and fuel the development of drugs needed to address current and future threats, as well as for improved oversight and stewardship to protect the effectiveness of existing drugs, the authors call for increased regulatory, governmental, industry, and scientific support and collaboration.
Enabling complex surgeries that include organ and bone marrow transplants, as well as cancer chemotherapy and successful care of preterm infants and others with weakened immune systems, effective antibiotics remain critical to benefitting from the advances of modern medicine. The Infectious Diseases Society of America will continue propose legislative, regulatory, and funding solutions to address the inadequate development of new medicines in the face of the growing crisis of infections resistant to existing antibiotics.
Source: IDSA
“A Coup Against Science”: Health Groups Decry Kennedy’s Firing of National Vaccine Advisory Panel
June 12th 2025Health leaders are outraged after HHS Secretary Robert F. Kennedy Jr. abruptly fired all 17 members of the CDC’s vaccine advisory panel, calling it a political purge that threatens public trust and vaccine safety.
AHE Exchange Summit 2025 Brings EVS and Infection Prevention Experts Together in Columbus, Ohio
June 9th 2025The Association for the Health Care Environment (AHE) is set to host its largest event of the year—Exchange Summit 2025—from June 8 to 11 in Columbus, Ohio. With over 600 environmental services (EVS) professionals expected to attend, this year’s conference focuses heavily on infection prevention, interdepartmental collaboration, and education that empowers frontline health care support leaders to improve patient safety and operational efficiency.